44 Milton Avenue
Alpharetta, GA 30009
United States
866 620 8655
https://www.virios.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Greg Duncan | Chairman & CEO | 798.67k | N/A | 1965 |
Mr. Ralph D. Grosswald M.P.H. | Sr. VP of Operations | 274.69k | N/A | 1969 |
Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer | 459.9k | N/A | 1956 |
Ms. Angela Walsh | CFO, SVP of Fin., Corp. Sec. & Treasurer | N/A | N/A | 1967 |
Ms. Carol Duffy Ph.D. | Chief Scientific Advisor | N/A | N/A | N/A |
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Virios Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.